Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB P65, ERK1/2 and P38 Signaling Pathway
Overview
Chemistry
Molecular Biology
Affiliations
Farrerol has been proved to have an anti-inflammatory effect. However, the effects of farrerol on mastitis have not been investigated. This study was aimed to investigate the effect and mechanism of farrerol in lipopolysaccharide (LPS)-induced mouse mastitis and LPS-induced inflammatory response of mouse mammary epithelial cells (mMECs). In vivo, LPS were injected to the tetrad pair of nipples for establishing mouse mastitis, and then tested the effect of farrerol on histopathological changes, inflammatory response and activation degree of protein kinase B (AKT), nuclear factor-kappa B p65 (NF-κB p65), p38, extracellular regulated protein kinase (ERK1/2). In vitro, the mMECs were incubated by farrerol for 1 h following by stimulating with LPS, and then the inflammatory response and the related signaling pathways were detected. The in vivo results found that farrerol could improve pathological injury of mammary gland, attenuate the activity of myeloperoxidase (MPO), inhibit the production of pro-inflammatory mediators and the phosphorylation of AKT, NF-κB p65, p38 and ERK1/2. The in vitro results also found farrerol inhibited inflammatory response and the related signaling pathways. Collectively, this study revealed that farrerol inhibits the further development of LPS-induced mastitis by inhibiting inflammatory response via down regulating phosphorylation of AKT, NF-κB p65, p38, and ERK1/2. These findings suggest that farrerol may be used as an anti-inflammatory drug for mastitis.
Nanocomposite Hydrogel for Real-Time Wound Status Monitoring and Comprehensive Treatment.
Lei H, Yu X, Fan D Adv Sci (Weinh). 2024; 11(42):e2405924.
PMID: 39269428 PMC: 11558094. DOI: 10.1002/advs.202405924.
Tu J, Liu Q, Sun H, Gan L Cell Biochem Biophys. 2024; 82(3):2427-2437.
PMID: 38878100 DOI: 10.1007/s12013-024-01353-2.
Huang H, Tang S, Zhou Y, Cai Y Immun Inflamm Dis. 2024; 12(5):e1077.
PMID: 38722267 PMC: 11080961. DOI: 10.1002/iid3.1077.
Li K, Yang M, Tian M, Jia L, Wu Y, Du J J Inflamm (Lond). 2024; 21(1):5.
PMID: 38395896 PMC: 10893599. DOI: 10.1186/s12950-024-00378-x.
Zhao R, Zhou X, Zhao Z, Liu W, Lv M, Zhang Z Mol Neurobiol. 2024; 61(9):7239-7255.
PMID: 38376762 DOI: 10.1007/s12035-024-04031-9.